Although cases involving the issue of written description must be decided on their own facts, a detailed disclosure may provide a greater chance of meaningful patent protection for genetic innovations.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
927 F.2d 1200 (Fed. Cir. 1991), cert. denied, 502 US 856 (1991).
Fiers v. Revel, 984 F.2d 1164, 1170–1171 (Fed. Cir. 1993).
Regents of the Univ. of California v. Eli Lilly & Co., 119 F.3d 1559, 1567–1568 (Fed. Cir. 1997).
378 F.3d 1330 (Fed. Cir. 2004).
Exemplary DNA patents are available through the DNA Patent Database, a joint project of the Kennedy Institute of Ethics, Georgetown University, and the Foundation of Genetic Medicine, http://dnapatents.georgetown.edu/
See, e.g., Univ. of Rochester v. G.D. Searle & Co., 375 F.3d 1303 (Fed. Cir. 2004).
Noelle v. Lederman, 355 F.3d 1343, 1349 (Fed. Cir. 2004) (internal quotes omitted).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Berman, R., Schoenhard, A. The level of disclosure necessary for patent protection of genetic innovations. Nat Biotechnol 22, 1307–1308 (2004). https://doi.org/10.1038/nbt1004-1307
Issue Date:
DOI: https://doi.org/10.1038/nbt1004-1307
